-

11:15:12 PM

JNJ Stock News

JNJ - Johnson & Johnson

10/20/21 6:38 PM

NYSE : JNJ

covid-19

Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA

Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least

RHEA-AI

negative

10/19/21 6:25 AM

NYSE : JNJ

Johnson & Johnson Reports Q3 2021 Results

Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2021. "Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical

RHEA-AI

neutral

10/15/21 4:11 PM

NYSE : JNJ

covid-19

Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee

Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted 19-0 to recommend Emergency Use Authorization (EUA) for

RHEA-AI

negative

10/14/21 10:38 PM

NYSE : JNJ

Johnson & Johnson Ovarian Cancer Victims Vow Fight to Stop J&J's Bankruptcy Scheme

Lawyers who represent more than 30,000 women who have filed lawsuits against Johnson & Johnson (NYSE:JNJ) in connection with its defective talc body powders, including the iconic Johnson's Baby Powder, say they will resist J&J's decision to use

RHEA-AI

very negative

10/14/21 5:55 PM

NYSE : JNJ

Johnson & Johnson Takes Steps to Equitably Resolve All Current and Future Talc Claims

Johnson & Johnson (NYSE: JNJ) (the Company) today announced that LTL Management LLC (LTL), a newly created and separate subsidiary of Johnson & Johnson, that was established to hold and manage claims in the cosmetic talc litigation, has filed for

RHEA-AI

neutral

10/13/21 6:45 AM

NYSE : JNJ

conferences

Johnson & Johnson to Host Business Review Highlighting Pharmaceuticals

Johnson & Johnson (NYSE: JNJ) will hold a Business Review for the investment community on Thursday, November 18, 2021, in which company leaders will share a detailed review of its Pharmaceuticals business, differentiated strategy and robust

RHEA-AI

neutral

10/12/21 4:15 PM

NYSE : JNJ

Johnson & Johnson Announces Jessica Moore as Vice President of Investor Relations

Johnson & Johnson (NYSE: JNJ) today announced the appointment of Jessica Moore to Vice President of Investor Relations for Johnson & Johnson, effective November 1, 2021. Ms. Moore will report to Mr. Joseph Wolk, Executive Vice President and Chief

RHEA-AI

neutral

10/12/21 6:45 AM

NYSE : JNJ

Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson To Retire, Effective December 31, 2021

Johnson & Johnson (NYSE: JNJ) today announced that Paul Stoffels M.D., currently Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson, will retire from the Company effective December 31, 2021.As the Vice

RHEA-AI

positive

10/11/21 4:45 PM

NYSE : JNJ

conferences

Johnson & Johnson to Participate in the Credit Suisse 30th Annual Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate virtually in the Credit Suisse 30th Annual Healthcare Conference on Wednesday, November 10 th. Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices will represent the Company in

RHEA-AI

neutral

10/06/21 11:00 AM

NYSE : JNJ

Janssen Announces Novel Mechanism of Action that Shows Promise Against Dengue in Data Published in Nature

The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today, in collaboration with the KU Leuven Rega Institute and the KU Leuven Centre for Drug Design and Discovery (CD3), the publication of new preclinical data in the journal

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

JNJ Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.jnj.com
CeoAlex Gorsky
Security nameJohnson & Johnson
Issue typecs
SectorManufacturing
Sic code2834
Employees134500
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address1 Johnson And Johnson Plz
StateNew Jersey
CityNew Brunswick
Zip08933-0001
CountryUS
Phone17325242455

JNJ Description:

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.